Mavefund EN
Aktis Oncology, Inc. logo

Aktis Oncology, Inc.

AKTS
Letzter Kurs (USD) US$25.82
Marktkapitalisierung (USD) US$1.5b
Kursänderung 12 Monate N/A
Loading the 12-month Mave Thesis and 1-month news signal

Start Heute Aktien Watchlist

Aktis Oncology, Inc. Überblick

Branche: Biotechnology: Pharmaceutical Preparations

Sektor: Health Care

Aktis Oncology is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. We see a significant opportunity to broaden the cancer patient populations benefiting from targeted radiopharmaceuticals by developing next-generation technologies that expand the scope of tumor targets for which it is possible to safely deliver a powerful payload of an alpha-emitting radioisotope. To ensure patient demand is reliably met, we are also establishing efficient end-to-end supply, with a combination of critical internal capabilities paired with established external vendors. Through these efforts, we seek to maximize clinical utility across multiple indications in multiple tumor types, and to expand the commercial uptake of radiopharmaceuticals beyond the traditional nuclear medicine setting and into the more expansive clinical oncology setting. Aktis Oncology is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. We see a significant opportunity to broaden the cancer patient populatio

Abdeckung eines neu notierten Unternehmens

Geprüftes Unternehmensprofil, Kursverlauf und SEC-Registrierungsquelle sind verfügbar.

SEC-Registrierungsdokument prüfen

Research-Überblick

Letztes Berichtsdatum 2026-08-13

Diese Mavefund-Research-Seite bündelt geprüfte Informationen zu Aktis Oncology, Inc. (AKTS): Unternehmensprofil, Kursverlauf, verknüpfte Primärquellen, verfügbare Finanzberichte, Research-Signale und zu prüfende Risiken.

Börsennotierung
AKTS · Nasdaq · MIC XNAS
Land
United States
Handelswährung
USD
Branche
Biotechnology: Pharmaceutical Preparations
Finanzdaten
Jahres- und Zwischenabschlüsse verfügbar
Letzte Primärquelle
SEC EDGAR · veröffentlicht 2026-08-13

Die Abdeckung wird automatisch aktualisiert und erst nach einer Datenintegritätsprüfung veröffentlicht. Nur Research-Unterstützung; keine persönliche Anlageberatung.

Mavefund ordnet die verfügbaren Fundamentaldaten, Bewertungskennzahlen und Risikofaktoren von Aktis Oncology, Inc. für einen nachvollziehbaren Research-Prozess ein.

Score

Veröffentlichte Ergebnisse

Was das Unternehmen berichtet hat – mit kompakter Quellenangabe.

Veröffentlicht Aug 13, 2026

Quarterly result summary

Revenue was $3.4M (+112% YoY). Net loss was -$24.1M (from $18.1M). R&D expense was $25.3M.

Revenue $3.4M +112% YoY
Net loss -$24.1M from $18.1M
R&D expense $25.3M reported
G&A expense $7M reported

Was sich verändert hat

  • Revenue +112% YoY to $3.4M.
  • Net loss was -$24.1M (from $18.1M).

Guidance / outlook

we expect to initiate the Phase 1b trial with AKY-2519 in B7-H3 expressing solid tumors, representing our third Phase 1b trial.

Earnings release Bericht öffnen

Source: SEC EDGAR company-filed earnings materials. Dates and source identifiers are retained for verification; review the original filing before relying on extracted report details.

Weitere aktuelle Ergebnisunterlagen

Geprüfte Signal-Evidenz

Aktuelle Nachrichten

Unternehmensrelevante Artikel aus Quellen, die die Relevanz- und Zuverlässigkeitsprüfung des Mave Signals bestehen.

Gewinn je Aktie

Score 2.00/5
Aktis Oncology, Inc. earns a low score, as its Earnings Per Share (EPS) has not shown continuous growth over the last six years. Notable counterparts in the sector with high scores includes Propanc Biopharma, Inc. Shoulder Innovations, Inc.
In Biotechnology: Pharmaceutical Preparations industry , Propanc Biopharma, Inc. , Ascentage Pharma Group International , Aardvark Therapeutics, Inc. are companies with high ratings.

Eigenkapitalrendite

Score 0.00/5
Aktis Oncology, Inc. exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Propanc Biopharma, Inc. Shoulder Innovations, Inc.
Aktis Oncolo... AKTS US$1.5b
Propanc Biop... PPCB US$29.5m
Shoulder Inn... SI US$669.5m

Nettomarge

Score 0.00/5
Aktis Oncology, Inc. olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Propanc Biopharma, Inc. Shoulder Innovations, Inc.
Aktis Oncolo... AKTS US$1.5b
Propanc Biop... PPCB US$29.5m
Shoulder Inn... SI US$669.5m

Aktienrückkäufe

In Biotechnology: Pharmaceutical Preparations industry , Propanc Biopharma, Inc. , Ascentage Pharma Group International , Aardvark Therapeutics, Inc. are companies with high ratings.

Verschuldung

Score 1.00/5
Aktis Oncology, Inc. registers a lower score in the category as a result of its elevated leverage ratio over the past six years compared to the sector median value. Conversely, other companies in the same sector, including Propanc Biopharma, Inc. Shoulder Innovations, Inc. have achieved high scores.
Aktis Oncolo... AKTS US$1.5b
Propanc Biop... PPCB US$29.5m
Shoulder Inn... SI US$669.5m

Finanzberichte

Vom Unternehmen veröffentlichte Berichtsdaten, strukturiert und mit der Originalquelle verknüpft.

Berichtswährung
Geprüfte, quellenverknüpfte Finanzberichte werden geladen, sobald dieser Abschnitt sichtbar wird.

Quellendetails werden mit den Berichtsdaten geladen. Die Werte sind standardisierte Unternehmensangaben zur Research-Unterstützung, keine persönliche Anlageberatung.

Finanzkennzahlen

Jährlich Quartalsweise

Finanzen
Profitabilität
Wachstum
Cashflow
Finanzielle Stabilität
Effizienzkennzahlen

Aktis Oncology, Inc. logo

Aktis Oncology, Inc.

US$25.82

US$1.5b

-0.50%

N/A